"I suggest that the state give policy guidance and support to the pharmaceutical and other intermediate industries, build a high-end pharmaceutical industry chain, and improve the source of the green and intrinsically safe intermediate industry." said Qiao Xu, member of the National Committee of the Chinese People's Political Consultative Conference and president of Nanjing University of Technology.

Qiao Xu pointed out that the current structural imbalance in my country's pharmaceutical and other intermediate industry chains is manifested in the convergence of product structures, single varieties, mostly overcapacity, and insufficient supply of mid-to-high-end products. Among them, the sales of pharmaceuticals and their intermediates are highly dependent on international orders, mainly concentrated in low-value-added bulk products such as vitamin C and penicillin, while higher-end pharmaceutical intermediates, specialty APIs and patented APIs often rely on imports.

“Due to the rising cost of investment in environmental protection equipment and limited production capacity, a group of companies have difficulty saving themselves. This has caused the pharmaceutical and other intermediate industries to be in the predicament of being'one size fits all' or'one size cut'. However, the new crown Under the circumstances, the development and production of prevention and control materials and vaccine drugs urgently need material support such as pharmaceuticals and other chemical intermediates." Qiao Xu said.

"The pharmaceutical and other intermediate industries have become an important direction for the development of fine chemicals in various countries because they can avoid patent barriers, and have the advantages of high investment profit rate and added value." Qiao Xu said, with the rise of anti-globalization and protectionism, foreign countries The risk of technological blockade and decoupling is increasing, and the risk of global chemical and pharmaceutical industry chains is also increasing.

He said that in order to cope with the test of possible disconnection in the pharmaceutical and other industries, we can start from three aspects:

Tap the potential inward and build an "internal circulation" industrial chain. Accelerate the promotion of domestically produced independent and controllable substitution plans, and promote the overall upgrade of the integrated internal recycling industry chain of "pharmaceutical intermediates, raw materials and preparations". Related industries should extend the industrial chain upstream and downstream, that is, closely connect with the production of basic chemical raw materials to avoid the monopoly of overseas key raw materials; at the same time, strengthen the end products such as raw materials and pharmaceutical preparations, customize the production of pharmaceutical intermediates, and increase the value chain. Manufacturing stays in the country.

Strengthen innovation and consolidate the technical support system. Attach importance to scientific research investment, establish various engineering technology centers across disciplines and high starting points to provide carriers for the research and development of new varieties of pharmaceutical intermediates and new processes. Focus on the prevention and treatment needs of major infectious diseases and respiratory diseases, target high-end drugs and their intermediates, encourage the inflow of talents and capital, adopt biotechnology and advanced green technology, improve the utilization of raw materials for the production of pharmaceuticals and their intermediates, and reduce pollutants Emissions to create a green process with low pollution, low energy consumption and high added value.

Strengthen clusters and create a "symbiotic system" featuring division of labor and cooperation, mutual benefit and win-win results. Encourage technological enterprises with strong strength to stand out, strengthen the integration of production factors and business process reengineering, and improve the level of industrial foundation and industry concentration. Encourage small and medium-sized enterprises to take advantage of being close to the market, rapid decision-making, and flexible mechanisms, take the differentiated product route, and cultivate a group of new "hidden champions" with high level of specialization and strong technical competitiveness in subdivisions.